论文部分内容阅读
目的了解住院患者病原学标本粪肠球菌(D群)的临床分布及其耐药性,为临床合理用药提供依据。方法通过临床标本细菌分离鉴定技术和药敏试验,对本医院住院患者感染患者送检标本进行粪肠球菌监测与分析。结果该医院在2012年度从住院患者感染标本中共分离出D群粪肠球菌212株,主要分离自尿液和胆汁标本。所分离的D群粪肠球菌对替考拉宁、替加环素、万古霉素、呋喃妥因、利奈唑烷均比较敏感。而对喹努普汀/达福普汀、红霉素、四环素耐药率在100%~50%。结论临床分离的D群粪肠球菌主要分布于泌尿道感染和消化道感染标本,且对临床常用抗菌药物普遍耐药。
Objective To understand the clinical distribution and drug resistance of Enterococcus faecalis (D group) in etiological specimens of inpatients, and to provide basis for clinical rational drug use. Methods By clinical specimens of bacterial isolation and identification techniques and susceptibility testing, the hospital inpatients infected patients were inspected Enterococcus faecalis monitoring and analysis. Results In 2012, 212 strains of Enterococcus faecalis D were isolated from the inpatients’ infected specimens and were mainly isolated from urine and bile samples. The isolated Enterococcus faecalis group D is relatively sensitive to teicoplanin, tigecycline, vancomycin, nitrofurantoin and linezolid. The quinoliptin / dalfopristin, erythromycin, tetracycline resistance rate of 100% to 50%. Conclusion The clinical isolates of Enterococcus faecium D mainly distribute in urinary tract infections and alimentary tract infections, and are generally resistant to common antibacterials.